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Commentary
To many readers of this journal, dichloro-
acetate (DCA) has a bad reputation that is 
mainly the result of its association with 
Superfund chemicals and other halogenated 
hydrocarbons of ill repute (Stacpoole et al. 
1998b), the findings of numerous animal stud-
ies implicating DCA in a variety of moder-
ate to life-threatening toxicities [International 
Agency for Research on Cancer (IARC) 
2004], and the ubiquity of this molecule in 
our biosphere that makes at least some degree 
of chronic exposure inevitable (Ammini and 
Stacpoole 2003; IARC 2004). Despite these 
concerns, the possibility that DCA might have 
a positive impact on certain human popu-
lations has been evident for half a century 
(Stacpoole 1989). Over time, DCA’s phar-
macological profile has created an interesting 
dialectic between environmental toxicologists, 
who consider it to be a hazard to humans, 
and clinical investigators, who are pursuing its 
therapeutic potential. Most ironic is the grow-
ing controversy over the relevance of DCA to 
human cancer, in which it is viewed as both a 
likely cause (IARC 2004) and a possible treat-
ment (Michelakis et al. 2010).
The DCA dilemma has been framed by 
three broad fields of science: epidemiological 
studies of populations exposed to environ-
mental levels of measured by-products of 
water disinfection or Superfund chemicals 
that are precursors of DCA; mechanism-
based toxicological experiments in which 
inbred rodent strains receive doses of DCA 
usually vastly higher than those to which 
most humans are exposed in the environ-
ment; and research in which subjects are 
administered DCA as a drug at doses similar 
to those used in animal toxicological inves-
tigations. Together, the data generated by 
such research address three questions that are 
at the heart of the DCA dilemma: Is DCA 
a significant environmental health hazard? 
Are certain populations at increased health 
risk or benefit? What are the important 
areas of future research that will help con-
firm, modify, or reject current opinions about 
DCA’s impact on human health?
Is DCA a significant environmental 
health hazard? Human populations have been 
exposed to DCA for generations, primar-
ily by ingesting chlorinated drinking water 
that may contain up to 160 µg/L (Miller 
and Uden 1983). Thus, consuming 2 L of 
municipal water may result in a DCA dose 
of approximately 2–4 µg/kg body weight in a 
70-kg human. However, studies of worldwide 
exposure to chlorinated drinking water in 
relation to human disease did not include an 
assessment of DCA exposure levels (Obolensky 
et al. 2003). Dermal absorption of DCA may 
occur when bathing or swimming in chlori-
nated pools or upon atmospheric exposure, 
although there are no good estimates of the 
contribution of dermal absorption to tissue 
or plasma levels of the compound. DCA is 
also considered a metabolite of the degreasing 
agent trichloroethylene (TCE) and related 
solvents, most of which are released into the 
atmosphere (Agency for Toxic Substances 
and Disease Registry 1997). TCE emis-
sions and contamination of surface water 
vary widely across the United States but cor-
relate broadly with population density and 
provide an estimated combined median daily 
intake by the general population of slightly 
> 13 µg/day (U.S. Geological Survey 2006). 
Both enzymatic (Lash et al. 2000) and nonen-
zymatic (Guengerich 2004) catalysis of TCE 
to DCA have been reported. However, the 
quantitative significance of either pathway is 
controversial (Ketcha et al. 1996; Merdink 
et al. 1998; Templin et al. 1995), which 
contributes to uncertainty about the relevance 
of environmental exposure levels of DCA to 
human health.
Nevertheless, considerable weight has 
been given to assigning causality to the oxida-
tive metabolites of TCE [see Supplemental 
Material, Figure 1 (doi:10.1289/ehp.1002554)] 
in evaluating the toxicity of DCA. Data from 
population-based pharmacokinetic modeling 
of the toxicokinetics and risk assessment of 
TCE and its metabolites (Chiu et al. 2009; 
Evans et al. 2009) indicate that TCE expo-
sure has been associated with toxicity to the 
kidney and liver and to the nervous, immune, 
and reproductive systems. How much of this 
information is relevant to the assessment of 
human risk from DCA exposure? Strong 
evidence from case–control studies indicates 
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an association between TCE exposure and 
renal cancer in humans (Brüning et al. 2003; 
Charbotel et al. 2006), but no experimental 
or clinical evidence is currently available to 
implicate DCA as a cause of this malignancy. 
Indeed, no epidemiological investigations have 
studied the carcinogenicity of DCA in humans. 
Lee et al. (2003) found a much weaker epide-
miological association between environmental 
exposure to TCE and liver cancer. In this case, 
however, the relationship between TCE and 
DCA becomes highly significant, because DCA 
is unquestionably a liver carcinogen in certain 
inbred strains of mice and rats (reviewed by 
IARC 2004; Stacpoole et al. 1998b). Most of 
the studies that have investigated the carcino-
genic potential of DCA have used drinking 
water or, occasionally, gavage to administer 
the compound for weeks or months at effective 
doses usually of 75 mg/kg/day or more [see 
Supplemental Material, Text A (doi:10.1289/
ehp.1002554)]. Regardless of the precise 
mechanism(s) that underlies DCA’s carcino-
genic potential, it is clear that hepatotoxicity in 
rodents from DCA is obtainable only at doses 
thousands of times greater than those to which 
humans are normally exposed from the com-
bined effects of the atmosphere and chlorinated 
drinking water. This fact, together with current 
data from population studies, does not sup-
port the postulate that exposure to DCA from 
environ  mental sources represents a general haz-
ard to humans. Whether chronic exposure to 
DCA at concentrations encountered in the 
environment or in the clinic is problematic to 
select human populations is addressed below.
Are certain populations at increased health 
risk or benefit? As a medicinal agent, DCA 
has been administered as the sodium salt in 
doses ranging from 10 to > 100 mg/kg/day by 
intravenous and oral routes for a few days to 
> 10 years [see Supplemental Material, Text 
B (doi:10.1289/ehp.1002554)]. These clinical 
studies have reported occasional asymptomatic 
increases in serum concentrations of alanine 
aminotransferase and aspartate aminotrans-
ferase that seldom exceeded two to three times 
the pretreatment values of these enzymes and 
that returned to pretreatment levels within a 
few weeks after the DCA dose was reduced or 
stopped (Barshop et al. 2004; Berendzen et al. 
2006; Stacpoole et al. 1998b). A more worri-
some toxicity of DCA is reversible peripheral 
neuropathy, an effect replicated in rodents, 
dogs, and humans (Stacpoole 1989). Clinical 
features include tingling of the fingers and toes 
and weakness of the facial and distal muscles 
of the extremities, accompanied by reduc-
tion in nerve conduction velocity in the sural 
and tibial nerves [see Supplemental Material, 
Text C (doi:10.1289/ehp.1002554)].
One possible explanation for the 
hepatic and neurological toxicity of DCA 
relates to the unusual consequences of its 
biotransformation. DCA is dehalogenated 
to glyoxylate by the cytosolic zeta-1 family 
isoform of glutathione transferase (GSTz1), 
which is identical to maleylacetoacetate 
isomerase (MAAI), the penultimate enzyme 
in the phenylalanine/tyrosine catabolic path-
way [see Supplemental Material, Figure 2 
(doi:10.1289/ehp.1002554)]. DCA causes a 
mechanism-based inhibition of GSTz1/MAAI 
(Anderson et al. 1999), an effect so profound 
as to significantly delay the plasma clearance 
of DCA at both environmental (micrograms 
per kilogram per day) and clinical (micro-
grams per kilogram per day) exposure levels 
in humans (Henderson et al. 1997; Jia et al. 
2006; Schultz and Shangraw 2006; Stacpoole 
et al. 1998a) [see Supplemental Material, Text 
D (doi:10.1289/ehp.1002554)].
Genetic or DCA-induced ablation of 
GSTz1/MAAI causes accumulation of the 
MAAI substrates maleylacetone and, presum-
ably, maleylacetoacetate (MAA) (Ammini 
et al. 2003; Cornett et al. 1999; Lim et al. 
2004; Tzeng et al. 2000), although the latter 
compound is too unstable to be detected 
by gas chromatography–mass spectrometry. 
Depending on exposure level, recovery of 
basal GSTz1/MAAI enzyme activity occurs 
over days to months after the withdrawal of 
DCA (Guo et al. 2006; Saghir and Schultz 
2002). The toxicological significance of inhi-
bition of MAAI is highlighted by the con-
sequences of loss of function mutations in 
fumarylacetoacetate (FAA) hydrolase, the ter-
minal enzyme of phenylalanine and tyrosine 
catabolism. Deficiency of this enzyme causes 
heredity tyrosinemia type 1 (hepatorenal 
tyrosinemia), an autosomal recessive disease 
that has an estimated prevalence of 100,000 
persons worldwide (Mitchell et al. 2001). In 
this disease, accumulation of the substrates 
for both the hydrolase and MAAI-catalyzed 
reactions are thought to be responsible for the 
dramatically increased risk of hepatocellular 
carcinoma in affected young children, because 
of the ability of MAA and FAA to form 
adducts (Lantum et al. 2002). This property 
is also shared by glyoxylate (Anderson et al. 
2004), the product of the GSTz1/MAAI-
mediated dehalogenation of DCA.
Another important consequence of 
tyrosinemia type 1 is the diversion of carbon 
precursors to succinylacetone, high urinary 
levels of which are diagnostic for the disease. 
Succinylacetone is a competitive inhibitor 
of δ-aminolevulinate dehydratase (enzyme–
inhibitor dissociation constant Ki = 0.3 µM; 
Sassa and Kappas 1983), which catalyzes an 
early step in heme biosynthesis. Inhibition 
of the dehydratase causes accumulation of 
δ-aminolevulinate, a neurotoxin that has been 
implicated in several peripheral neuropa-
thies, including lead poisoning (see Felitsyn 
et al. 2008). Increased concentrations of 
δ-aminolevulinate or subsequent perturba-
tions in heme metabolism or both are thought 
to be the cause of the neurological mani-
festations of tyrosinemia type 1, including 
peripheral neuropathy (Lindberg et al. 1999; 
Mitchell et al. 2001). Given the effects of 
DCA on GSTz1/MAAI function, it is note-
worthy that increased urinary concentrations 
of maleylacetone and δ-aminolevulinate 
have been measured in children who were 
treated for months or years with DCA. 
For some of these children, maleylacetone 
levels approached or exceeded those found 
in children with hereditary tyrosinemia 
type 1 (Shroads AL, Langaee T, Coats BS, 
Kurtz TL, Bullock JR, Weithorn D, Gong Y, 
Wagner DA, Ostrov DA, Johnson JA, 
Stacpoole PW, unpublished observations) [see 
Supplemental Material, Text E (doi:10.1289/
ehp.1002554)].
Recently, age and GSTz1/MAAI geno-
type have emerged as important determinants 
of clinical toxicity from DCA. For example, 
in a randomized clinical trial of 43 children 
(mean age at entry, 5.6 years) with congen-
ital forms of lactic acidosis, Stacpoole et al. 
(2006) found no difference in clinical or 
biochemical adverse effects, including hema-
tological, hepatic, and peripheral nerve func-
tion, between those children who received 
25 mg/kg/day of sodium DCA and those who 
received placebo for 6 months. In contrast, 
a controlled clinical trial of 30 patients with 
mitochondrial encephalomyopathy, lactic 
acedosis, and stroke-like episodes (MELAS) 
whose mean age at entry was 30 years, ended 
prematurely because of drug-associated 
neurotoxicity (Kaufmann et al. 2006). In exam-
ining the plasma kinetics of DCA in a repre-
sentative sample of children and adults from 
both trials, a striking age-dependent decrease 
was discovered in plasma DCA clearance that 
was replicated in rats (Shroads et al. 2008); this 
finding confirmed and extended earlier obser-
vations in rodents (James et al. 1998; Schultz 
et al. 2002). Furthermore, delayed clearance 
of DCA in rats was associated with increased 
urinary excretion of DCA, maleyl  acetone, and 
monochloro  acetate (a putative neurotoxin 
and a very minor product of DCA metabo-
lism) and with a decrease in urinary oxalate, an 
end product of DCA biotransformation [see 
Supplemental Material, Figure 1 and Text F 
(doi:10.1289/ehp.1002554)].
Age alone does not account entirely for 
variability in the kinetics and biotransforma-
tion of DCA. The human GSTz1/MAAI 
gene contains four nonsynonymous single-
nucleotide polymorphisms, with products 
that show different activities toward DCA 
and variable frequencies among ethnic and 
racial groups (Lim et al. 2004; Stacpoole et al. 
2008; Shroads AL, Langaee T, Coats BS, 
Kurtz TL, Bullock JR, Weithorn D, Gong Y, The dichloroacetate dilemma
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Wagner DA, Ostrov DA, Johnson JA, 
Stacpoole PW, unpublished observations). 
Using 1,2-13C-DCA, several researchers were 
able to clearly segregate “slow” and “fast” 
metabolizers of DCA, based on GSTz1/MAAI 
(Shroads AL, Langaee T, Coats BS, Kurtz TL, 
Bullock JR, Weithorn D, Gong Y, Wagner DA, 
Ostrov DA, Johnson JA, Stacpoole PW, 
unpublished observations). Those who metab-
olized DCA slowly showed markedly delayed 
plasma clearance and biotransformation, 
increased excretion of unmetabolized drug [see 
Supplemental Material, Figure 3 (doi:10.1289/
ehp.1002554)], and increased urinary accumu-
lation of maleylacetone and δ-aminolevulinate. 
Atomic modeling of the effect of GSTz1/MAAI 
polymorphism showed that variants associated 
with slow DCA metabolism induced structural 
changes in the enzyme homodimer leading 
to protein instability or abnormal protein–
protein interactions. These data suggest that 
GSTz1/MAAI haplotype may predict, at least 
in part, the toxicogenetics of DCA. Moreover, 
such information may be used prospectively to 
adjust dosing and mitigate the risk of adverse 
events from DCA.
Despite the potential toxicity of DCA, 
its therapeutic potential continues to be 
investigated. Its principal site of pharma-
codynamic action is the mitochondrial 
pyruvate dehydrogenase (PDH) complex 
(Stacpoole 1989), a gatekeeper enzyme for 
regulating carbohydrate fuel metabolism in 
cells [see Supplemental Material, Figure 4   
(doi:10.1289/ehp.1002554)]. Under aerobic 
conditions, PDH catalyzes the rate-determining   
step in glucose oxidation by irreversibly 
decarboxylating pyruvate to acetyl coenzyme 
A, thereby “priming” the Krebs cycle with 
glucose carbon. In addition, both the PDH-
catalyzed reaction and several enzymes of the 
Krebs cycle generate reducing equivalents in 
the forms of nicotine adenine dinucleotide 
and flavin adenine dinucleotide that are 
used by the respiratory chain for the reduc-
tion of molecular oxygen to water and for 
ATP synthesis from ADP. PDH is revers-
ibly phosphorylated and inactivated by a 
family of PDH kinase (PDK) isoforms that 
exhibit variable tissue expression (Sugden 
and Holness 2003). DCA exerts differential 
inhibition on PDKs to maintain PDH in its 
unphosphorylated, catalytically active form 
and exerts greatest inhibition (Ki = 0.2 mM) 
(Bowker-Kinley et al. 1998) toward the ubiq-
uitously expressed PDK2. Because pyruvate 
is in equilibrium with lactate, it follows that 
acquired or congenital deficiencies of PDH 
may lead to mitochondrial energy failure and 
lactate accumulation. Accordingly, DCA has 
been used to improve mitochondrial energet-
ics and to mitigate tissue or systemic lactic 
acidosis (see Stacpoole et al. 1992, 2006 and 
references therein).
Invoking the same site and mechanism 
of action described above, several laboratories 
have reported DCA’s selective proapoptotic 
and antiproliferative effects when administered 
in vitro to a variety of cultured human tumor 
cells or to human tumors implanted into 
immunocompromised rodents (reviewed 
by Michelakis et al. 2008). The rationale 
for considering DCA as an anticancer drug 
is predicted on the well-established finding 
that solid tumors derive most of their energy 
from glycolysis, rather than through mito-
chondrial oxidative phosphorylation, even in 
the presence of adequate oxygen availability. 
This phenomenon is called the Warburg 
effect and is now known to be a consequence 
of the combined transactivation of glucose 
membrane transporters, glycolytic enzymes, 
and PDK (Vander Heiden et al. 2009). 
Consequently, PDH activity and oxidative 
phosphorylation are inhibited in most can-
cers. By inhibiting PDK in tumor cells, DCA 
stimulates PDH and oxidative phosphoryla-
tion, decreases tumor lactate concentration, 
and initiates a caspase-mediated chain of 
reactions leading to apoptosis of tumor, but 
not of host, cells (Bonnet et al. 2007) [see 
Supplemental Material, Text G (doi:10.1289/
ehp.1002554)].
Primary arterial hypertension repre-
sents another neoplastic (but nonmalignant) 
condition in which mitochondrial dysfunc-
tion and hyperproliferation of cells lining 
the pulmonary vasculature lead to increased 
pulmonary vascular resistance, failure of the 
right ventricle of the heart, and premature 
death. In animal models of primary arterial 
hypertension, DCA has been shown to pre-
vent or reverse mitochondrial damage and 
cellular proliferation, improve lung function, 
and increase survival by its ability to stimu-
late oxidative phosphorylation and induce 
apoptosis in proliferating cells (Bonnet et al. 
2006; McMurtry et al. 2004; Michelakis et al. 
2002). Results from clinical trials of DCA in 
this disease have not yet been reported [see 
Supplemental Material, Text H (doi:10.1289/
ehp.1002554)].
What are important areas of future 
research? Few chemicals have integrated the 
disciplines of environmental science and 
clini  cal research as effectively as DCA. Recent 
studies investigating the toxico  genetics of this 
compound when administered as a drug have 
important implications for human popu-
lations chronically exposed to environmen-
tally relevant concentrations. The findings 
are particularly germane to persons in con-
tact with water sources contaminated with 
TCE or other industrial solvents or who are 
administered drugs that may be biotrans-
formed to DCA (reviewed by Stacpoole et al. 
1998b). The recent discovery of a mitochon-
drial GSTz1/MAAI (Li et al. 2011) indicates 
that both the biotransformation of DCA 
and the site of its major pharmacodynamic 
action, the PDH complex, occur within the 
matrix of this organelle. This finding raises 
intriguing questions about whether the stim-
ulation of PDH activity and, subsequently, 
the respiratory chain by DCA could generate 
sufficient amounts of reactive oxygen spe-
cies to cause oxidative damage to mitochon-
drial GSTz1/MAAI and further impair DCA 
metabolism.
New epidemiological research on DCA 
should focus more selectively on populations 
that may be predisposed to DCA-associated 
health complications because of age or geno-
type. For example, individuals with an inborn 
error of the phenylalanine and tyrosine cata-
bolic pathway could suffer additional adverse 
consequences when exposed to clinically, 
and perhaps even environmentally, relevant 
doses of DCA. Individually, these diseases are 
rare. However, perhaps the most common 
of these conditions, hyperphenyl    alaninemia 
(which includes phenylketonuria), has a 
worldwide annual incidence that varies widely 
from approximately 3 to > 300 per million 
births (Scriver et al. 2001). Another popu-
lation at potential risk is persons prone to 
hyperoxaluria. For example, primary hyper-
oxaluria has a prevalence of > 1 per 10,000 
persons and may cause widespread calcium 
oxalate crystal deposition (Danpure 2001). 
Such individuals could be at heightened risk 
for developing calcium oxalate deposits were 
they to receive clinical doses of DCA over 
long periods of time.
Likewise, humans who metabolize DCA 
slowly may also be genetically predisposed to 
exhibit reduced flux through the phenylala-
nine and tyrosine catabolic pathway. Chronic 
consumption of a high-protein diet by such 
individuals could lead to an accumulation 
of toxic tyrosine intermediates, with adverse 
consequences for hepatic, neurological, and 
other organ system failure. Testing this pos-
tulate could involve studies of stable isotope 
amino acid kinetics in relation to GSTz1/
MAAI haplotype. Finally, careful consid-
eration must be given to age and genotype 
when conducting future treatment-oriented 
research with DCA, particularly cancer trials 
involving adults.
DCA has so far been proven to be neither 
a major environmental health hazard nor a 
panacea for human ills. Future clinical and 
environmental research on this unusual mole-
cule should be focused increasingly on under-
standing its impact on biological processes 
in discrete subpopulations of humans with 
known GSTz1/MAAI genotype. We continue 
to move incrementally, but steadily, from 
puzzled observations about the pharmacology 
of DCA to established conclusions about its 
effect on human health.Stacpoole
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